Prioritizing prevention of HIV and sexually transmitted infections: First-generation vaginal microbicides

Current Opinion in Infectious Diseases

Volumn 19, Issue 1, 2006, Pages 49-54

  Madan, Rebecca Pellett ^a   Keller, Marla J ^a   Herold, Betsy C ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Division of Infectious Diseases   (United States)

Author keywords

Genital herpes; Herpes simplex virus; Human immunodeficiency syndrome; Sexually transmitted infections; Topical microbicides

Indexed keywords

ACIDFORM; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BUFFER; C 31 G; CARBOPOL 974P; CARRAGEENAN; CELLACEFATE; CELLULOSE SULFATE; DAPIVIRINE; DETERGENT; MICROBICIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NONOXINOL 9; POLYMER; POLYNAPHTHALENE SULFONATE; PRO 2000; RNA DIRECTED DNA POLYMERASE INHIBITOR; SURFACTANT; TENOFOVIR; UNCLASSIFIED DRUG; VIVAGEL;

ANTIVIRAL ACTIVITY; CELL MEMBRANE; CHLAMYDIA TRACHOMATIS; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG SPECIFICITY; FEMALE GENITAL SYSTEM; GENITAL HERPES; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NEISSERIA GONORRHOEAE; NONHUMAN; PH; REVIEW; SEX ROLE; SEXUALLY TRANSMITTED DISEASE; SKIN IRRITATION; TARGET CELL; TOXICITY TESTING; VIRUS INACTIVATION; VIRUS PARTICLE;

EID: 29744461100     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000200291.37909.3b     Document Type: Review

References (69)

1. Pilcher CD, Hsiao CT, Eron JJ, et al. Brief but efficient: acute HIV Infection and the sexual transmission of HIV. J Infect Dis 2004; 189:1785-1792. A well-written paper discussing the high risk of viral transmission during acute HIV infection and its relationship to the HIV pandemic.
2. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2:33-42. This paper summarizes the synergistic relationship between HIV and STIs, as well as the period of hyperinfectivity during acute HIV infection.
3. Cohen M. HIV and sexually transmitted diseases: lethal synergy. Top HIV Med 2004; 12:104-107. A discussion of how STIs, including chlamydia, gonorrhea, and genital herpes, facilitate HIV transmission.
4. Koelle DM, Wald A. HSV: the importance of asymptomatic shedding. J Antimicrob Chemother 2000; 45 (suppl T3):1-8.
5. Mbopi-Keou FX, Gresenguet G, Mayaud P, et al. Interaction between HSV-2 and HIV-1 infection in African women: opportunities for intervention. J Infect Dis 2000; 182:1090-1096.
6. Serwadda D, Gray RH, Sewankambo NK, et al. HIV acquisition associated with genital ulcer disease and HSV-2 infection: a nested case-control study in Rakai, Uganda. J Infect Dis 2003; 188:1492-1497.
7. Corey L, Wald A, Patel R, et al. Once daily valacyclovir to reduce the risk of transmission of genital herpes. NEJM 2004; 350:11-20. Discusses the rationale of oral valacyclovir in limiting HSV, and possibly HIV, transmission.
8. Corey L, Wald A, Celum CL, et al. The effects of HSV-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004; 35:435-445. A thorough review of the problematic relationship between HIV and HSV.
9. Moss GB, Overbaugh J, Welch M, et al. HIV DNA in urethral secretions in men: association with gonococcal urethritis and CD4 cell depletion. J Infect Dis 1995; 172:1469-1474.
10. Eron JJ, Gilliam B, Fiscus S, et al. HIV-1 shedding and chlamydial urethritis. JAMA 1996; 275:36.
11. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet 1997; 349:1868-1873.
12. McClelland RS, Wang CC, Mandaliya K, et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 2001; 15:105-110.
13. World Health Organization/Global Programme on AIDS. Management of STDs. WHO/GPM/TEM/94.1. Geneva: World Health Organization; 1994.
14. Wolday D, Gebremariam Z, Mohammed Z, et al. The impact of syndromic treatment of sexually transmitted diseases on genital shedding of HIV-1. AIDS 2004; 18:781-785.
15. Hardy E, de Padua KS, Hebling EM, et al. Women's preferences for vaginal antimicrobial contraception V: attitudes of Brazilian women to the insertion of vaginal products. Contraception 2003; 67:391-395.
16. Johnston R. Microbicides 2002: an update. AIDS Patient Care STDs 2002; 16:419-430.
17. Van Damme L, Niruthisard S, Atisook R, et al. Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS 1998; 12:433-437.
18. Van Damme L, Chandeying V, Ramjee G, et al. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 Phase II study group. AIDS 2000; 14:85-88.
19. Fichorova RN, Tucker LD, Anderson DJ, et al. The molecular basis of nonoxynol-9 induced vaginal inflammation and its possible relevance to HIV-1 transmission. J Infect Dis 2001; 184:418-428.
20. Van Damme L, Ramjee G, Alay M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomized controlled trial. Lancet 2000; 360:971-977.
21. Ballagh S, Baker JM, Henry DM, et al. Safety of single daily use for one week of C31G HEC gel in women. Contraception 2002; 66:369-375.
22. Mauck CK, Creinin MD, Barnhart KT, et al. A Phase I comparative post coital testing study of three concentrations of C31G. Contraception 2004; 70:227-231.
23. Catalone BJ, Kish-Catalone TM, Nelly EB, et al. Comparative safety evaluation of the candidate vaginal microbicide C31G. Antimicrob Agent Chemother 2005; 49:1509-1520. This paper reviews the difficulties of testing detergents as candidate microbicides and discusses both in vivo and in vitro models for evaluating the safety of C31G.
24. Scordi-Bello IA, Mosoian A, He C, et al. Candidate sulfonated and sulfated topical microbicides: comparison of anti HIV activities and mechanism of action. Antimicrob Agent Chemother 2005; 49:3607-3615. An excellent review of the mechanisms of sulfonated polymers and the in-vitro techniques used to evaluate efficacy.
25. Cheshenko N, Keller MJ, MasCasullo V, et al. Candidate topical microbicides bind HSV glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agent Chemother 2004; 48:2025-2036. This paper discusses the interactions between host cells and viral particles during HSV invasion, as well as the mechanism by which sulfonated polymers interfere with this process.
26. Rusconi S, Moonis M, Merill DP, et al. Naphthalene sulfonate polymers with CD4-blocking and anti-HIV-1 activities. Antimicrob Agent Chermother 1996; 40:234-236.
27. Greenhead P, Hayes P, Watts DS, et al. Parameters of HIV infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000; 74:5577-5586.
28. Weber J, Nunn A, O'Connor T, et al. 'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV 89.6pp in vitro and in vivo. AIDS 2001; 15:1563-1568.
29. Cheshenko N, Keller MJ, MasCasullo V, et al. Candidate topical microbicides bind HSV glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agent Chemother 2004; 48:2025-2036.
30. Anderson RA, Feathergill K, Diao X, et al. Evaluation of poly(styrene-4-sulfonate) as a preventive agent for conception and STDs. J Androl 2000; 21:862-875.
31. Herold BC, Bourne N, Marcellino D, et al. Poly(sodium 4-styrene sulfonate): an effective candidate topical antimicrobial for the prevention of STDS. J Infect Dis 2000; 181:770-773.
32. Bourne N, Bernstein DI, Ireland J. The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model. J Infect Dis 1999; 180:203-205.
33. Cheshenko N, Keller MJ, MasCasullo V. Candidate topical microbicides bind HSV glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agent Chemother 2004; 48:2025-2036.
34. Scordi-Bello IA, Mosoian A, He C, et al. Candidate sulfonated and sulfated topical microbicides: comparison of anti HIV activities and mechanism of action. Antimicrob Agent Chemother 2005; 49:3607-3615.
35. Mayer KH, Karim SA, Kelly C, et al. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 2003; 17:321-329.
36. Tabet SR, Callahan MM, Mauck CK, et al. Safety and acceptability of penile application of two candidate topical microbicides, BufferGel and PRO 2000 gel: 3 randomized trials, in healthy low-risk men and HIV positive men. J Acquir Immune Defic Syndr 2003; 33:476-483.
37. Van Damme L, Wright A, Depraetere K, et al. A Phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex Transm Infect 2000; 76:126-130.
38. Keller MJ, Zerhouni-Layachi B, Cheshenko N, et al. PRO 2000 gel inhibits HIV and HSV infection following vaginal application: a double blind placebo-controlled trial. J Infect Dis 2006; 193 (in press).
39. Baba M, Snoeck R, Pauwels R, et al. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including HSV, CMV, VSV, and HIV. Antimicrob Agents Chemother 1988; 32:1742-1745.
40. Maguire RA, Bergman N, Philips M, et al. Comparison of microbicides for efficacy in protecting mice against vaginal challenge with HSV-2, cytotoxicity, antibacterial properties, and sperm immobilization. Sex Transm Dis 2001; 28:260-265.
41. Carlucci MJ, Scolano LA, Noseda MD, et al. Protective effect of a natural carrageenan on genital HSV infection in mice. Antiviral Res 2004; 64:137-141.
42. Spencer SE, Valentin-Bon IE, Whaley K, et al. Inhibition of Neisseria gonorrhoeae genital tract infection by leading candidate topical microbicides in a mouse model. J Infect Dis 2004; 189:410-419.
43. Coetzee N, Housen A, Blanchand K, et al. A randomized, placebo controlled double blind safety trial of Carraguard microbicide gel in South Africa: signs and symptoms of genital irritation. Microbicides; 12-15 May 2002; Antwerp, Belgium. Abstract B-069.
44. Anderson RA, Feathergill KA, Diao XH, et al. Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J Androl 2002; 23:426-438.
45. Mauck C, Weiner DH, Ballagh S, et al. Single and multiple exposure tolerance study of cellulose sulfate gel: a Phase I safety and colposcopy study. Contraception 2001; 64:383-391.
46. Mauck C, Frezieres R, Walsh T, et al. Cellulose sulfate: tolerance and acceptability of penile application. Contraception 2001; 64:377-381.
47. Mauck C, Weiner DH, Ballagh S, et al. Single and multiple exposure tolerance study of cellulose sulfate gel: a Phase I safety and colposcopy study. Contraception 2001; 64:383-391.
48. Witvrouw M, Fikkert V, Pluymers W, et al. Polyanionic (i.e. polysulfonate) dendrimers can inhibit the replication of HIV by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the viral replication cycle. Mol Pharmacol 2000; 58:1100-1108.
49. Jiang YH, Emau P, Cairns JS, et al. SPL 7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV in macaques. AIDS Res Hum Retroviruses 2005; 21:207-213. A well-written discussion of the role of animal models in microbicide testing.
50. Herold BC, Scordi-Bello I, Cheshenko N, et al. Mandelic acid condensation polymer: novel candidate microbicide for prevention of HIV and HSV entry. J Virol 2002; 76:11236-11244.
51. Otten RA, Adams DE, Kim CN, et al. Multiple vaginal exposures to low doses of R5 SHIV: strategy to study HIV preclinical intervention in nonhuman primates. J Infect Dis 2005; 191:164-173.
52. O'Connor TJ, Kinchington D, Komgro HI, et al. The activity of candidate virucidal agents, low pH and genital secretions against HIV-1 in vitro. Int J STD AIDS 1995; 6:267-272.
53. Pettit RK, McAllister SC, Hamer TA. Response of gonococcal clinical isolates to acidic conditions. J Med Microbiol 1999; 48:149-156.
54. Zhen H, Alcom TM, Cohen MS. Effects of H202 producing lactobacilli on Neisseria gonorrhoeae growth and catalse activity. J Infect Dis 1994; 170:1209-1215.
55. Mahmoud EA, Svensson LO, Olsson SE, et al. Antichlamydial activity of vaginal secretions. Am J Obstet Gynecol 1995; 172:1268-1272.
56. Kempf D, Jentsch P, Barre-Sinoussi FB, et al. Inactivation of HIV by low pH and pepsin. J Acquir Immune Defic Syndr 1991; 4:828-830.
57. Garg S, Anderson RA, Chany CJ, et al. Properties of a new acid buffering bioadhesive vaginal formulation (ACIDFORM). Contraception 2001; 64:67-75.
58. Amaral E, Faundes A, Zaneveld L, et al. Study of the vaginal tolerance to ACIDFORM, acid buffering bioadhesive gel. Contraception 1999; 60:361-366.
59. Zeitlin L, Hoen TE, Achilles SL, et al. Tests of BufferGel for contraception and prevention of STDs in animal models. Sex Transm Dis 2001; 28:417-423.
60. Patton DL, Sweeney YC, Cummings PK, et al. Safety and efficacy evaluation for vaginal and rectal use of BufferGel in the macaque model. Sex Transm Dis 2004; 31:290-296.
61. Cohen J. Prevention cocktails: combining tools to stop HIVs spread. Science 2005; 309:1002-1005. This article discusses the urgent need for microbicides, as well as the difficulties of testing microbicides, particularly antiretroviral drugs, in human subjects.
62. Balzarini J, Van Herrewege Y, Vanham G, et al. Metabolic activity of nucleoside and nucleotide reverse transcriptase inhibitors in dendritic and Langerhans cells. AIDS 2002; 16:2159-2163.
63. Van Herrewege Y, Michiels J, Van Roey J, et al. In vitro evaluation of non-nucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as HIV microbicides. Antimicrob Agent Chemother 2004; 48:337-339. This article provides a new look at antiretroviral medications used as topical microbicides.
64. DiFabio S, VanRoey J, Giannini G, et al. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC 120 in a gel formulation. AIDS 2003; 17:1597-1604.
65. Fletcher P, Kiselyeva Y, Wallace G, et al. The non-nucleoside reverse transcriptase inhibitor UC 781 inhibits HIV-1 infection of human cervical tissue and dissemination by migratory cells. J Virol 2005; 79:11179-11186. A discussion of the use of the cervical explant model in microbicide testing.
66. Liu S, Lu H, Neurath AR, et al. Combination of candidate microbicides Cellulose Acetate 1,2-Benzenedicarboxylate and UC781 has synergistic and complementary effects against HIV type I infection. Antimicrob Agents Chemother 2005; 49:1830-1836.
67. Cohen J. Prevention cocktails: combining tools to stop HIV's spread. Science 2005; 309:1002-1005.
68. Veazey RS, Shattock RJ, Pope M, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9:343-346.
69. Tasi CC, Emau P, Jiang Y, et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission model. AIDS Res Hum Retroviruses 2004; 20:11-18.